LIPERCOSYL

This brand name is authorized in France, Ireland

Active ingredients

The drug LIPERCOSYL contains a combination of these active pharmaceutical ingredients (APIs):

1 Atorvastatin
UNII 48A5M73Z4Q - ATORVASTATIN CALCIUM TRIHYDRATE

Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase. Atorvastatin lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG-CoA reductase and subsequently cholesterol biosynthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.

Read about Atorvastatin
2 Perindopril
UNII TFT5IM1KGB - PERINDOPRIL ARGININE

Perindopril is an inhibitor of the enzyme that converts angiotensin I into angiotensin II (Angiotensin Converting Enzyme ACE). The converting enzyme, or kinase, is an exopeptidase that allows conversion of angiotensin I into the vasoconstrictor angiotensin II as well as causing the degradation of the vasodilator bradykinin into an inactive heptapeptide. Inhibition of ACE results in a reduction of angiotensin II in the plasma, which leads to increased plasma renin activity (by inhibition of the negative feedback of renin release) and reduced secretion of aldosterone. Since ACE inactivates bradykinin, inhibition of ACE also results in an increased activity of circulating and local kallikrein-kinin systems (and thus also activation of the prostaglandin system).

Read about Perindopril

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
LIPERCOSYL Capsules, hard Health Products Regulatory Authority (IE) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
C10BX15 C Cardiovascular system → C10 Lipid modifying agents → C10B Lipid modifying agents, combinations → C10BX Lipid modifying agents in combination with other drugs
Discover more medicines within C10BX15

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: FR Base de donnรฉes publique des mรฉdicaments Identifier(s): 61580888, 65050983, 65177678, 66399379, 67180783, 69806588
Country: IE Health Products Regulatory Authority Identifier(s): 24542, 24543, 24544, 24546, 24548, 24549

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.